http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
-
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
-
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
-
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022
-
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022
-
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
-
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
-
Akero Therapeutics (AKRO) Reports Phase 2b HARMONY Study Achieved Statistical Significance in Both EFX Doses
-
In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks
-
In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks
-
Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASH
-
Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASH
-
Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment
-
Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment
-
InSphero Wins Sino-European Innovation Award for Breakthrough NASH Discovery and Safety Testing Platform
